MedTrace Logo

Pembrolizumab + Defactinib In Pleural Mesothelioma

NCT04201145 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-11-17

No results posted yet for this study

Summary

This research study is studying a new drug combination of Pembrolizumab and Defactinib followed by surgical resection possible treatment for resectable Malignant Pleural Mesothelioma (MPM).

The names of the study drugs involved in this study are:

* Pembrolizumab
* Defactinib

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

Pembrolizumab

IV, predetermined dosage, twice per cycle

DRUG

Defactinib

Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort

Sponsors & Collaborators

Principal Investigators

  • Raphael Bueno, MD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201145 on ClinicalTrials.gov